```html

Immune Thrombocytopenic Purpura (ITP)

Overview

Immune thrombocytopenic purpura (ITP), also called immune thrombocytopenia, is an acquired autoimmune disorder in which the body’s immune system mistakenly attacks and destroys platelets—the blood cells responsible for clotting. This results in a low platelet count (thrombocytopenia) and an increased tendency to bleed or bruise.

ITP can affect anyone, but it is most common in:

• Children ages 2–5 years (often following a viral infection).
• Adults aged 20–50 years, with a slight female predominance (approximately 60 % of adult cases).

Overall prevalence in the United States is estimated at 1–2 per 10,000 adults and 4–6 per 100,000 children (CDC, 2022). The condition is chronic in about 30–50 % of adults, whereas many children experience a self‑limited episode that resolves within 6–12 months.

Symptoms

Symptoms result from low platelet numbers and range from mild bruising to life‑threatening bleeding. Common signs include:

• Easy bruising (purpura) – purple or red patches on the skin, often on the arms or legs.
• Petechiae – tiny (1–2 mm) red or purple dots that look like a rash, usually on the lower legs.
• Nosebleeds (epistaxis) – frequent or prolonged bleeding from the nostrils.
• Bleeding gums – may occur after brushing teeth or spontaneously.
• Heavy menstrual bleeding (menorrhagia) – common in women of reproductive age.
• Blood in urine or stool – can appear as pink/red urine or black, tarry stools (melena).
• Prolonged bleeding from cuts – wounds that take longer than usual to stop bleeding.
• Fatigue – may be related to anemia secondary to chronic bleeding.
• Headache, dizziness, or visual changes – signals possible intracranial bleeding and requires urgent evaluation.

Causes and Risk Factors

ITP is primarily an autoimmune process, but the exact trigger is often unknown. Key mechanisms and risk factors include:

Immune Mechanisms

• Autoantibody‑mediated platelet destruction: IgG antibodies bind platelet surface glycoproteins (most commonly GPIIb/IIIa), marking them for removal by spleen macrophages.
• Impaired platelet production: Antibodies may also affect megakaryocytes in the bone marrow, reducing new platelet formation.

Potential Triggers

• Recent viral infections (e.g., Epstein–Barr virus, cytomegalovirus, HIV, hepatitis C).
• Vaccinations (rarely, after MMR or COVID‑19 vaccines; benefits of vaccination outweigh risks).
• Medications such as quinine, heparin, or certain antibiotics that can induce drug‑dependent antibodies.
• Underlying autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease).

Risk Factors

• Female sex (especially in adults).
• Age > 60 years – associated with a higher likelihood of chronic disease.
• Previous episode of ITP – recurrence rates approach 30 %.
• Coexisting autoimmune disorders.

Diagnosis

Diagnosing ITP is one of exclusion—ruling out other causes of thrombocytopenia. The typical work‑up includes:

History and Physical Examination

• Detailed bleeding history (onset, frequency, severity).
• Search for clues of secondary causes (recent infections, drug exposures, systemic illness).
• Examination for petechiae, purpura, splenomegaly, or lymphadenopathy.

Laboratory Tests

• Complete blood count (CBC) with peripheral smear: Isolated low platelet count with normal white‑cell and red‑cell lines. Smear shows small platelets, indicating increased turnover.
• Basic metabolic panel: To assess kidney and liver function before certain medications.
• Coagulation profile (PT/INR, aPTT): Usually normal in ITP, helping differentiate from disseminated intravascular coagulation.
• HIV, hepatitis C serology: Recommended because chronic viral infections can cause secondary ITP.
• Antinuclear antibody (ANA) panel: If systemic autoimmune disease is suspected.

Bone Marrow Examination

Reserved for patients with atypical features (e.g., age > 60 years with pancytopenia, unexplained anemia, or suspicion of malignancy). Findings are usually normal or show increased megakaryocytes.

Diagnostic Criteria (per American Society of Hematology)

• Platelet count < 100 × 10⁹/L (100,000/µL) without another identifiable cause.
• Presence of bleeding symptoms or risk thereof.

Treatment Options

Treatment decisions balance platelet count, bleeding severity, patient age, comorbidities, and personal preferences. Not all patients require immediate therapy; observation is appropriate for asymptomatic adults with platelet counts > 30 × 10⁹/L.

First‑Line Therapies

• Corticosteroids: Prednisone 1 mg/kg daily (up to 4 weeks) or dexamethasone 40 mg daily for 4 days. They suppress antibody production but have side‑effects (weight gain, glucose intolerance, mood changes).
• Intravenous immunoglobulin (IVIG): 1 g/kg daily for 1–2 days. Provides rapid platelet rise (useful for severe bleeding or before surgery). Effect is transient (2–4 weeks).
• Anti‑D immunoglobulin (RhIG): For Rh‑positive, non‑splenectomized patients. Works similarly to IVIG but is less commonly used.

Second‑Line / Chronic Management

• Thrombopoietin receptor agonists (TPO‑RAs):
  • Eltrombopag (Orliga) – oral, started at 50 mg daily.
  • Romiplostim (Nplate) – subcutaneous weekly injection.
  Both increase platelet production and are FDA‑approved for chronic ITP. Monitoring liver function (eltrombopag) and bone marrow reticulin is required.
• Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly × 4). Useful in patients with autoimmune overlap; remission can last months to years.
• Splenectomy: Surgical removal of the spleen yields durable remission in ~60–70 % of adults, but carries lifelong infection risk. Generally reserved after failure of medical therapy.
• Mycophenolate mofetil, azathioprine, or cyclophosphamide: Immunosuppressive agents for refractory cases.

Adjunctive Measures

• Platelet transfusions: Only for life‑threatening hemorrhage or before urgent surgery; transfused platelets are rapidly destroyed in active ITP.
• Avoidance of antiplatelet drugs: Aspirin, NSAIDs, and certain herbs (e.g., ginkgo) increase bleeding risk.

Lifestyle & Supportive Care

• Maintain adequate calcium and vitamin D intake if on long‑term steroids.
• Vaccinate against encapsulated organisms (pneumococcus, meningococcus, Haemophilus influenzae) if splenectomy is performed.
• Regular dental hygiene to prevent gum bleeding.

Living with Immune Thrombocytopenic Purpura

While ITP can be unsettling, many people lead active, normal lives with appropriate management.

Daily Management Tips

• Monitor platelet counts: Every 1–3 months initially, then spaced out if stable.
• Watch for bleeding signs: Daily self‑check for new bruises, petechiae, or gum bleeding.
• Protect yourself from injury: Use protective gear for contact sports, avoid knives with loose blades, and trim fingernails short.
• Oral care: Soft toothbrush, avoid aggressive flossing, and use alcohol‑free mouthwash.
• Travel precautions: Carry a medical alert bracelet, a copy of your treatment plan, and a small supply of rescue medication (e.g., steroids or IVIG on call).
• Women’s health: Discuss menstrual management with a gynecologist; hormonal IUDs are generally safe, but high‑dose estrogen contraceptives may increase clot risk.

Psychosocial Support

Living with a chronic autoimmune disease can cause anxiety. Consider:

• Support groups (online forums, local ITP patient organizations).
• Counseling or cognitive‑behavioral therapy for stress management.
• Education of family, friends, and schools/employers about the condition.

Prevention

Because ITP is largely idiopathic, primary prevention is limited. However, risk can be reduced by:

• Prompt treatment of infections—especially viral illnesses that are known triggers.
• Avoiding unnecessary medications that can provoke immune thrombocytopenia (e.g., quinine, certain antibiotics).
• Ensuring up‑to‑date vaccinations (influenza, COVID‑19, hepatitis B) to lower infection‑related triggers.
• Maintaining a healthy immune system through balanced diet, regular exercise, and adequate sleep.

Complications

If left untreated or inadequately controlled, ITP can lead to serious outcomes:

• Severe hemorrhage: Intracranial, gastrointestinal, or retroperitoneal bleeding, which can be fatal.
• Chronic anemia: Resulting from ongoing microscopic blood loss.
• Medication side‑effects: Long‑term steroids can cause osteoporosis, diabetes, cataracts, and hypertension.
• Post‑splenectomy infections: Increased susceptibility to encapsulated bacteria; lifelong antibiotic prophylaxis may be indicated.
• Psychological impact: Depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Immune thrombocytopenic purpura (ITP).” Updated 2023. https://www.mayoclinic.org
2. American Society of Hematology. “Guidelines for the Management of ITP.” Blood, 2022; 139(1): 45‑56.
3. CDC. “Immune Thrombocytopenic Purpura (ITP) Fact Sheet.” 2022. https://www.cdc.gov
4. National Institutes of Health, National Library of Medicine. “Thrombocytopenia.” MedlinePlus, 2023. https://medlineplus.gov
5. Cleveland Clinic. “Immune Thrombocytopenic Purpura (ITP) Treatment.” 2023. https://my.clevelandclinic.org
6. World Health Organization. “Guidelines on the Management of Bleeding Disorders.” 2021.

```